AbbVie Inc
Biotechnology
AbbVie Inc (ABBV) Stock News
The latest ABBV headlines and market coverage — 3 recent stories, updated throughout the day.
- Zacks Investment Research·
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie has recently attracted investor attention with shares returning +4.3% over the past month, outperforming the S&P 500's +2.1% gain. However, despite strong earnings growth expectations (+104.3% YoY for current quarter) and consistent beats on both EPS and revenue estimates, the company received a Zacks Rank #4 (Sell) rating due to recent downward revisions in consensus earnings estimates. The stock is valued at par with peers (C grade) but may underperform the broader market in the near term.
- Zacks Investment Research·Neutral
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie is a trending stock with strong earnings growth expectations of +40.5% for the current fiscal year and +14.8% for next year. The company has consistently beaten consensus estimates over the trailing four quarters. However, with a Zacks Rank #3 (Hold) rating and a C valuation grade indicating it trades at par with peers, the stock is expected to perform in line with the broader market in the near term.
- Zacks Investment Research·
AbbVie (ABBV) Advances While Market Declines: Some Information for Investors
AbbVie stock rose 1.78% to $261.70, outperforming a declining S&P 500. The company has gained 3.07% over the past month, exceeding sector losses. Analysts expect strong earnings growth of 107.53% YoY with revenue projected at $17.36 billion (+10.02% YoY). AbbVie holds a Zacks Rank #3 (Hold) with a Forward P/E of 18.3, trading at a premium to its industry average.